{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T06:40:42Z","timestamp":1756190442875,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s12328-021-01396-5","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T17:02:41Z","timestamp":1617382961000},"page":"858-865","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Durable response after discontinuation of pembrolizumab therapy for intrahepatic cholangiocarcinoma: a case report"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-0465","authenticated-orcid":false,"given":"Shimpei","family":"Eguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroji","family":"Shinkawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunori","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kozo","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigekazu","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Amano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenjiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go","family":"Ohira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Tauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Shirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,2]]},"reference":[{"key":"1396_CR1","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","volume":"60","author":"J Bridgewater","year":"2014","unstructured":"Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268\u201389.","journal-title":"J Hepatol"},{"key":"1396_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/hepr.13438","volume":"50","author":"M Kubo","year":"2020","unstructured":"Kubo M, Izumi N, Kubo S, et al. Report of the 20th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2020;50:15\u201346.","journal-title":"Hepatol Res"},{"key":"1396_CR3","doi-asserted-by":"publisher","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","volume":"27","author":"JW Valle","year":"2016","unstructured":"Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v28\u201337.","journal-title":"Ann Oncol"},{"key":"1396_CR4","doi-asserted-by":"crossref","unstructured":"Watson GA, Doi J, Hansen AR, et al. Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift? Br J Clin Pharmacol. 2020;86:1753\u201368","DOI":"10.1111\/bcp.14355"},{"key":"1396_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II keynote-158 study. J Clin Oncol. 2020;38:1\u201310.","journal-title":"J Clin Oncol"},{"key":"1396_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00073","volume":"1","author":"R Bonneville","year":"2017","unstructured":"Bonneville R, Krook MA, Kautto EA, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. 2017;1:1\u201315.","journal-title":"JCO Precis Oncol"},{"key":"1396_CR7","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1200\/JCO.2020.38.4_suppl.803","volume":"38","author":"K Akagi","year":"2020","unstructured":"Akagi K, Oki E, Taniguchi H, et al. Natiowide large-scale investigation of microsatellite instability status in more than 18,000 patients with various advanced solid cancers. J Clin Oncol. 2020;38:803.","journal-title":"J Clin Oncol"},{"key":"1396_CR8","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer."},{"key":"1396_CR9","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common dominator approach to cancer therapy. Cancer Cell. 2015;27:450\u201361.","journal-title":"Cancer Cell"},{"key":"1396_CR10","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1186\/s12885-018-5021-2","volume":"18","author":"H Mou","year":"2018","unstructured":"Mou H, Yu L, Liao Q, et al. Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report. BMC Cancer. 2018;18:1105.","journal-title":"BMC Cancer"},{"key":"1396_CR11","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.2169\/internalmedicine.4588-20","volume":"59","author":"A Naganuma","year":"2020","unstructured":"Naganuma A, Sakuda T, Murakami T, et al. Microsatellite instability-high intrahepatic cholangiocarcinoma with portal vein tumor thrombosis successfully treated with pembrolizumab. Intern Med. 2020;59:2261\u20137.","journal-title":"Intern Med"},{"key":"1396_CR12","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.21873\/anticanres.14411","volume":"40","author":"M Nakamura","year":"2020","unstructured":"Nakamura M, Ueno M, Hayami S, et al. Effective response of intrahepatic cholangiocarcinoma to pembrolizumab: a case report. Anticancer Res. 2020;40:4123\u20139.","journal-title":"Anticancer Res"},{"key":"1396_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/4719194","volume":"2017","author":"G Viale","year":"2017","unstructured":"Viale G, Trapani D, Curigliano G. Mismatch repair deficiency as a predictive biomarker for immunotherapy efficacy. Biomed Res Int. 2017;2017:1\u20137.","journal-title":"Biomed Res Int"},{"key":"1396_CR14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.critrevonc.2017.06.001","volume":"116","author":"SM Vareki","year":"2017","unstructured":"Vareki SM, Garrigos C, Duran I. Biomarkers of response to PD-1\/PD-L1 inhibition. Crit Rev Oncol Hematol. 2017;116:116\u201324.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1396_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34.","journal-title":"Genome Med"},{"key":"1396_CR16","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1373\/clinchem.2019.303644","volume":"65","author":"MJ Duffy","year":"2019","unstructured":"Duffy MJ, Crown J. Biomarkers for predicting response to immunotherapy with immune checkpoint inhibitors in cancer patients. Clin Chem. 2019;65:1228\u201338.","journal-title":"Clin Chem"},{"key":"1396_CR17","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomized, open-label, phase 3 study. Lancet. 2019;394:1915\u201328.","journal-title":"Lancet"},{"key":"1396_CR18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","volume":"392","author":"K Shitara","year":"2018","unstructured":"Shitara K, Ozguroglu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392:123\u201333.","journal-title":"Lancet"},{"key":"1396_CR19","doi-asserted-by":"publisher","first-page":"VIII210","DOI":"10.1093\/annonc\/mdy282.009","volume":"29","author":"M Ueno","year":"2018","unstructured":"Ueno M, Chung HC, Nagrial A, et al. Pembrolizumab for advanced biliary adenocarcinoma: Results from the multicohort, phase 2 KEYNOTE-158 study. Ann Oncol. 2018;29:VIII210.","journal-title":"Ann Oncol"},{"key":"1396_CR20","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/ijc.33013","volume":"147","author":"SA Piha-Paul","year":"2020","unstructured":"Piha-Paul SA, Oh DY, Ueno M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020;147:2190\u20138.","journal-title":"Int J Cancer"},{"key":"1396_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409\u201313.","journal-title":"Science"},{"key":"1396_CR22","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509\u201320.","journal-title":"N Engl J Med"},{"key":"1396_CR23","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1158\/1078-0432.CCR-15-1678","volume":"22","author":"JC Dudley","year":"2016","unstructured":"Dudley JC, Lin MT, Le DT, et al. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res. 2016;22:813\u201320.","journal-title":"Clin Cancer Res"},{"key":"1396_CR24","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","volume":"79","author":"J Siegel","year":"2018","unstructured":"Siegel J, Totonchy M, Damsky W, et al. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol. 2018;79:1081\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"1396_CR25","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","volume":"36","author":"C Robert","year":"2018","unstructured":"Robert C, Ribas A, Hamid O, et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol. 2018;36:1668\u201374.","journal-title":"J Clin Oncol"},{"key":"1396_CR26","doi-asserted-by":"publisher","first-page":"e59125","DOI":"10.1172\/jci.insight.59125","volume":"3","author":"A Osa","year":"2018","unstructured":"Osa A, Uenami T, Koyama S, et al. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight. 2018;3:e59125.","journal-title":"JCI Insight"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-021-01396-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-021-01396-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-021-01396-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T12:56:28Z","timestamp":1724763388000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-021-01396-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,2]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1396"],"URL":"https:\/\/doi.org\/10.1007\/s12328-021-01396-5","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"type":"print","value":"1865-7257"},{"type":"electronic","value":"1865-7265"}],"subject":[],"published":{"date-parts":[[2021,4,2]]},"assertion":[{"value":"15 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shimpei Eguchi, Hiroji Shinkawa, Yasunori Sato, Kozo Nakai, Shigekazu Takemura, Shogo Tanaka, Ryosuke Amano, Kenjiro Kimura, Go Ohira, Kohei Nishio, Masahiko Kinoshita, Jun Tauchi, Toru Miyazaki, Atsushi Ishihara, Daisuke Shirai and Shoji Kubo declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights"}},{"value":"Informed consent was obtained from all patients for being included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}